Clinical Trial

129 Xenon Imaging in Patients Treated With Sotatercept

Study acronym: Sox-PH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-04-02; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2026-02-23
Trial Details
NCT Number NCT06351345
Lead Sponsor Bastiaan Driehuys
Collaborators: Merck Sharp & Dohme LLC
Conditions Pulmonary Hypertension, Pulmonary Arterial Hypertension
Enrollment 14 participants
Start Date 2025-10-27
Primary Completion 2029-02-04 (estimated)
Study Completion 2030-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-24